Pharma’s big patent cliff, more obesity fundraising, and a failed ALS study

Why could we see more deal-making at this year’s J. P. Morgan Healthcare conference? Why are investors concerned about a slowdown in U.S. biotech innovation? And what are the hosts’ New Year’s resolutions?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

For more on the industry’s looming patent cliff, go here; to read more about the new obesity startup, go here; and to learn more about Calico’s failed study, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.

Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax

Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are racing madly about the Pharmalot grounds

October 24, 2023

MSOS Stock analysis – The DEA Announcement & M&A Activity

January 12, 2024

Epinephrine Was First an Asthma Treatment

This is the first in an occasional series on the origin of commonly used medicines. When epinephrine was first discovered at the turn of the

November 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.